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baseline and 3 months in 344/383 patients who took1 dose of study drug. Patients
were obese (mean [ SD] BMI  32.3 [ 7.7] kg/m2) and 80% had T2DM. Mean
HbA1c was 9.1% ( 1.5) at baseline and 8.3% ( 1.2) after 3 months; 11.6% reached
HbA1c7%. The mealtime insulin dose at 3 months was 38.6 IU ( 28.0). A cluster of
4 factors that favourably affected glycaemic control was identified: T2DM, lower
baseline HbA1c1 hypoglycaemic event, and being Caucasian. Patients with T1DM
and those taking at least one cardiovascular medication were less likely to reach
target. Comparing the overall p-values for the crude and adjusted odds ratios sug-
gested that HbA1c at baseline, type of diabetes and higher number of hypoglycae-
mic events were interrelated, while racial group was independent of the other
factors. CONCLUSIONS: Patients who achieved HbA1c 7.0% 3 months after the
addition of insulin glulisine were likely to have T2DM, a lower baseline HbA1c, more
hypoglycaemic episodes and be Caucasian.
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OBJECTIVES: To assess the clinical and economic benefits associated with ade-
quate and early insulin initiation and intensification in people with T2DM.
METHODS: A systematic review was performed using published papers from Jan-
uary 2000 to August 2010 that assessed intervention, disease, study design and
outcomes. Studies were classified as initiation and intensification based on pre-
defined criteria. Individual studies from systematic reviews and meta-analysis
identified in our review were searched and included if relevant. RESULTS: We
screened 2690 articles, of which 76 (40 initiation and 36 intensification) studies
were included. Baseline HbA1c values were in all initiation studies8.5%. Endpoint
HbA1c values were reduced with insulin in all studies, with endpoint values rang-
ing from 6.6% to 9.8%. Similar baseline and endpoint HbA1c were seen with the
intensification studies (endpoint HbA1c ranging from 6.4% to 9.6%). Addition of
insulin to oral anti-diabetic agents (OADs) resulted in better glycaemic control in
most studies. Blood glucose levels reduced substantially with OADsinsulin com-
pared to OADs alone. Quality of life outcomes and treatment satisfaction were
reported in six studies and not significantly different for insulin versus OADs.
Hypoglycaemic events were lower with insulin initiation versus OADs (1.391.16
vs. 2.301.87; 9/27 vs. 17/28). However, all insulin types were associated with
weight gain though the comparison with OADs elicited varying results. Economic
outcomes were reported in four studies with insulin initiation. Some studies reported
a reduced incidence in diabetes-related complications with insulin, resulting in lower
diabetes-related medical and total healthcare costs in these patients. Two studies
showed that initiating insulin in those failing OADs resulted in increase in life expec-
tancy and quality-adjusted life expectancy. CONCLUSIONS: Proactive management
of uncontrolled glycaemia in people with T2DM should be considered with early
insulin initiation and intensification. Further studies are required to explore the
economic benefits with early insulin initiation and intensification.
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OBJECTIVES: To analyse the use of hypoglycemic drugs in Serbia from pharmaco-
therapeutic and pharmacoeconomic point. To see the influence of pharmacother-
apeutic guidelines and cost on use of hipoglicemic drugs when compared with the
countries with developed pharmacotherapy. METHODS: Use of hypoglicemic
drugs in Serbia was obtained from National Agency for drugs in Serbia (ALIMS). The
costs of hypoglycemic drugs was obtained from Serbian reimbursment company.
The use of drugs was expressed in DDD/1000 inh/day, and compared to the price of
drugs in the cathegory. RESULTS: The total use of hypoglycemic drugs in Serbia (56
DDD/1000inh/day) was similar to the use of drugs in this cathegory in another
countries. Use of insulins was lower in Serbia, probably because slightly different
pharmacotherapeutic approach to DM Typ II in Serbia. The structure of oral hypo-
glycemics was similar in Serbia and in comparator countries (Norway, Finland).
While metformin was the most often used hypoglicemic drug in countries with
developed pharmacotherapy, in Serbia the most often used drugs were sulfonyl-
urea drugs, with glibenclamide and gliclaside being in the first place. Gliclaside,
being on the second place in Serbia, is the most expensive hypoglicemic drug (price
per DDD 12.15 Serbian dinars). If gliclaside would be changed with another, less
expensive drug, the national reimbursment company would spare significant
amount of money. Glimepiride, the most often used and the cheaper sulfonylurea
derivative in countries with developed phrmacotherapy, was on the third place in
Serbia. CONCLUSIONS: The total use of hypoglycemics in Serbia is comparable to
countries with developed pharmacotherapy, indicating the satisfiing level of the
treatment of diabetes mellitus. However, the structure og hypoglycemics used is
suboptimal from pharmacotherapeutic and from pharmacoeconomic point of
wiev. Significant improvement are needed, which would improve pharmacother-
apy and pharmacoeconomic aspect of use of this drugs.
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OBJECTIVES: To assess the characteristics of type 2 diabetes patients treated with
vildagliptin (a new DPP-4 inhibitor) and to evaluate potential misuse, treatment
adherence, effectiveness and tolerability of vildagliptin under real-life conditions
of care in France.METHODS: Following a request by the French Health Technology
Agency (Haute Autorité de Santé) an observational cohort study was started in
2010. The study population included a representative sample of patients with type
2 diabetes initiating a treatment with vildagliptin. Patients were enrolled through a
national sample of vildagliptin prescribers Data collected included sociodemo-
graphic characteristics, clinical history, comorbidities, detailed treatment and lab-
oratory data, physical exam and adherence. RESULTS: Overall, 482 GPs and 84
endocrinologists enrolled 1702 patients. Sixty percent were males, mean age was
63 (11) years, mean disease duration was 7 (6.5) years and mean HbA1C 7.8%
(1.2). Forty-five percent were obese and 39% overweight, 70% were treated for
hypertension and 66% for dyslipidaemia, and 1256 patients (74%) were treated with
vildagliptin/metformin fixed combination (Eucreas, FC) and 442 (26%) with vilda-
gliptin (Galvus). Main reasons for initiating vildagliptin were: previous treatment
failure (82%), weight gain (17%), reducing the numbers of pills (16%) and intolerance
to a previous treatment (12%). In accordance to the precautions of use, 1366 pa-
tients (80%) underwent liver function tests, and 1552 patients (91%) blood creati-
nine measurement prior to treatment initiation. In few cases, vildagliptin was
prescribed to patients for whom the product was not recommended: at baseline,
2.1% of treated patients presented elevations in alanine/aspartate aminotransfer-
ase  3 times the upper limit of normal, 0.3% a NYHA class III congestive heart
failure (no class IV) and 9.3% did not respect the precautions of use for renal
function. CONCLUSIONS: Most prescriptions of vildagliptin were in accordance
with the summary of product characteristics in this large, randomly selected
French population.
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OBJECTIVES: Off-label is defined by the Turkish Ministry of Health (MoHT) as the
use of licensed pharmaceutical products in doses outside of or exceeding the scope
of the registered indication, and the use of non-licensed but imported medicinal
products for the purpose of individual treatment. The use of off-label or non-
licensed endocrinology medicines were evaluated in order to provide an under-
standing of Turkey’s perspective within this area of healthcare provisions.
METHODS: A computer search was performed of IEGM’s database. A patient base
using off-label endocrinology medicine applications from 19 June 2009 to 19 June
2010 were searched. RESULTS: The computer search for the showed that 357 ap-
plications were submitted for off-label endocrinology medicine use. It was con-
cluded that the highest application percentage was established by “osteoporosis”
in all of the applications (43%, 155/357). The highest application was established by
Ankara province (28%, 44/155). University hospitals had the highest off-label osteo-
porosis medicine use applications within the given timeline (65%, 102/155). Spe-
cialized physicians in the fields of endocrinology and metabolism (adult and pae-
diatric) had the highest number of off-label osteoporosis applications (71%, 111/
155). It was concluded that the highest application percentage was established by
“teriparatide use in osteoporosis” (87%, 136/155) in all of the osteoporosis applica-
tions. 92 of 136 applications were approved. There was a significiant difference
between the T score (L1-4) of rejected and approved applications for patients
(3.071,85 and 3.231.63, respectively) (p0.001). Yet there was not a significiant
difference between ages of patients for whom applications were rejected or
approved. CONCLUSIONS: It could be said that off-label use can lead to reimburse-
ment restrictions in endocrinology, especially for teriparatide-like oncology med-
icines. In Turkey, physicians who want to prescribe an off-label or non-licensed
pharmaceutical or a medicine which has a different use from reimbursement in-
dications, need to apply through the off-label medicine use process.
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OBJECTIVES: Xerosis is a common disorder among diabetic patients; 82.1% of dia-
betic patients suffer from xerosis, which may or may not be combined with fissures
or cracking. It causes disorders which play a major role in the onset of ulceration.
Xerosis exacerbates the development and the recurrence, in particular, of hyper-
keratosis. To evaluate, under real use conditions, the effect of Pedimed (Glycerine,
petroleum jelly, piroctone olamine, tocopheryl nicotinate, hydroalcoholic ruscus
extr) on diabetic foot. METHODS: Observation study of diabetic patients with high
risk factor for foot ulceration in Australian centres, with data collected via ques-
tionnaires from patients receiving PediMed® to measure acceptability and xerosis
assessment from physicians and healthcare professionals. RESULTS: Mean age of
subjects is 57 years ( 13.3), 64% presenting with type 2 diabetes. The XAS score
measured by the doctor at inclusion is 6.4 ( 2.4) and 6.3 ( 2.6), respectively for the
right and left foot. At 4 weeks, measured by the same doctor, the XAS score is 2.7 (
2.3) and 3.0 ( 2.3) respectively for the right and left foot. Improvements are statis-
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tically significant for both feet (p0.001). Hyperkeratosis of both feet, evaluated by
the doctor, significantly improves after 4 weeks of treatment. The efficacy score
measured by the patient is 16.4 ( 4.8) on inclusion. Measured under the same
conditions, it is 7.7 ( 3.2) at 4 weeks. The difference is statistically significant
(p0.001). Treatment compliance is good since 89% confirm that they respected the
dosage, a trend confirmed by the fact that 94% of subjects say that they are satisfied
with the product.CONCLUSIONS: By means of a validated score (XAS) and a patient
evaluation scale, the efficacy of Pedimed in treating the diabetic foot is confirmed.
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OBJECTIVES: The objective of this study was to estimate a prevalence of diabetes
mellitus (DM) among patients with micro- and macrovascular complications in
Poland, like angina pectoris, myocardial infarction (MI), stroke, lower limb isch-
emia, end-stage renal disease (ESRD), and their consequences like heart failure,
visual disorders or amputations. METHODS: The estimation was based on obser-
vational studies, which were identified by searching medical databases and Polish
registries. Publications were selected in a specific order, to ensure that included
data are the most representative for Polish population. Firstly, studies conducted in
Polish settings were included and, if no reliable publications were found, European,
non-European Caucasian and other (not specified) population were analyzed. Pop-
ulation based registries were considered as the most appropriate type of data.
When no registry was available systematic reviews of observational studies were
included. If systematic review was not available – data from clinical studies were
taken into account. RESULTS: According to polish registries, DM was present in
28% of patients with non-ST-elevation MI, 20% of patients with ST-elevation MI,
22% of patients with unstable angina and 22% patients with ESRD. The results of
two studies regarding Polish population indicate that 15.3% of patients with stable
angina pectoris suffer from DM. The results of studies coming from European coun-
tries identified by literature search showed that DM was diagnosed in 26.2% of
patients with heart failure, 21.5% of patients with stoke, 40% of patients hospital-
ized for peripheral artery disease, 52.8% of patients with lower-extremity amputa-
tion and 67.1% of patients with non-traumatic amputations. Diabetes was present
in 34.9%, 9.4% and 7.1% of patients with retinopathy, vision disorders and blindness
respectively. CONCLUSIONS:DM often co-exists with vascular disorders in Poland.
It affects 15% of patients with macrovascular complications and more than 20% of
patients with microvascular complications.
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OBJECTIVES: To evaluate the effect of A1C variability on the risk of developing new
diabetes in healthy adults in Japan. METHODS: Population-based, retrospective
cohort from 2005 to 2008 in Tokyo, Japan. In healthy adults not taking diabetes
medication and with lower than 6.5 of HbA1c at baseline, we measured annually
the serum HbA1c and calculated the annual visit-to-visit variability. RESULTS: At
baseline, 14,764 people (49% female) with a mean age of 50 years old (SD: 12 years,
range: 23 to 92), a mean fasting plasma glucose (FPG) level of 98.4 mg/dl (SD: 9.3
mg/dl) and a mean HbA1c level of 5.3 % (SD: 0.4 %) had annual check-ups over 4
years. Using the multivariate logistic regression, the A1C variability (odds ratio
(OR): 7.8 for highest quantile interval ( 0.16%)) versus the lowers quantile (0.08
%), 95%CI: 4.8 – 12.8) and the baseline A1C (OR: 43.3 for group with 6.0 – 6.4 % of A1C
versus with 5.0 %, 95% CI: 10.4 – 181.4) were independently predictive of new
diabetes after adjusting for the other potential risk factors. FPG (OR: 1.1, 95%CI: 1.1
– 1.2) and Smoker (OR: 1.6, 95%CO: 1.2 – 2.3) also significantly related to develop the
new diabetes.CONCLUSIONS:Visit-to-visit variability in A1C independently added
to the baseline A1C in predicting the risk of developing new diabetes for the healthy
adults.
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OBJECTIVES: Beta cells in the pancreas are responsible for secreting insulin in
response to increases in blood glucose. Proinsulin C-peptide (C-peptide), co-se-
creted with insulin, is a marker for beta cell function. C-peptide levels at type 1
diabetes (T1D) diagnosis and rate of decline (ROD) post diagnosis are important
when evaluating the potential beta cell-preserving therapies to maintain better
glycemic control and reduce complications. Because little is known about factors
that affect C-peptide levels at diagnosis and ROD, we aimed to summarize known
factors. METHODS: We conducted a systematic review of literature in PubMed
(English only) from 1987 using the following key words alone and in combination:
type 1 diabetes, c-peptide, rate of decline, concentration, epidemiology, residual
beta cell function, diagnosis. Additionally articles were identified from the refer-
ence lists of selected journal articles. RESULTS: The review indicated that: 1) De-
cline of beta-cell function begins years before T1D diagnosis; 2) At diagnosis stim-
ulated C-peptide concentrations range from 0.320.26 pmol/mL (meanSD) to
1.40.8 pmol/mL (meanSD); 3) Stimulated C-peptide ROD can range from -0.00 to
-0.01 pmol/mL/month; 4) Lower C-peptide concentrations at diagnosis are partly
explained by younger onset age, time since diagnosis, genetic factors and a high-
titer presence of islet cell autoantibodies; and 5) Intensive therapy to treat T1D of
3 insulin injections daily reduces the C-peptide level after 1 year by 0.210.03
pmol/mL versus 0.150.02 pmol/mL for less intensive treatment of 1-2 injections.
CONCLUSIONS: Understanding the factors that influence C-peptide ROD may help
researchers develop strategies which address heterogeneity of response to ther-
apy, resulting in improved glycemic control and reduction in complications such as
ketoacidosis, neuropathy or nephropathy. Including parameters for C-peptide and
its ROD in pharmacoeconomic models may help estimate the burden of these
complications in T1D, and help quantify the benefits of preserving beta cells.
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OBJECTIVES: The safety and efficacy of exenatide BID (exenatide) compared to
insulin glargine (glargine) has been studied in clinical trials and use of exenatide
has been associated with reductions in A1C and weight. This study examined the
clinical outcomes of exenatide versus glargine in patients with type 2 diabetes in a
‘real-world’ ambulatory care setting. METHODS: A retrospective analysis was con-
ducted using the General Electric electronic medical record database to select ex-
enatide (n4,494) and glargine (n5,424) cohorts. These cohorts were propensity-
score matched to control for baseline demographic, clinical, and resource use
variables (2,683 matched pairs). Matched cohorts were compared using paired t-
tests and nonparametric tests as appropriate. The effectiveness endpoints were
changes in A1C (primary endpoint), weight, body mass index (BMI), blood pressure
(BP), lipid levels, and hypoglycemia rates. RESULTS: The matched exenatide and
glargine cohorts had comparable age (58 vs. 58 years), females (55% vs. 53%), and
baseline clinical characteristics. In a 12-month follow-up period, the exenatide
cohort achieved greater mean (SD) reduction in A1C (-0.66% [1.5] versus -0.41%
[1.7], P0.01), weight (-2.6 [6.8] vs. -0.2 [9.2] kg, P0.01), BMI (-0.9 [2.6] versus
-0.1 [2.7] kg/m2, P0.01), and systolic BP (-1.8 [17] vs. -0.3 [18] mmHg, P0.01).
More exenatide-treated patients reached the A1C goal of7% (46% vs. 36%, P0.01).
There were no clinically significant differences in diastolic BP, lipid levels, and
hypoglycemia rates between cohorts. CONCLUSIONS: Exenatide-treated patients
experienced significantly greater reductions in A1C, weight, BMI, and systolic BP
than the glargine cohort. These results demonstrated the clinical effectiveness of
exenatide compared to glargine in a large, diverse, ‘real-world’ patient population
treated in the ambulatory care setting.
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OBJECTIVES: According to HTA reports regarding long-acting insulin analogues
(LAIA) these drugs should be reserved for use in selected diabetic patients only. In
line with recent knowledge LAIA in Poland are planned to be reimbursed in frame-
work of therapeutic programme (LAIA-TP). This study assess the impact of this
decision on public health-payers budget. METHODS: The analysis was perfomed
using modelling technique, based on systematic review of LAIA, Polish epidemio-
logic and costing data. Two scenarios were compared: (A) LAIA not reimbursed, (B)
LAIA reimbursed for patients with episodes of severe hypoglicaemia (after 6
months reimbursement continued only in patients successfully treated). In each
scenario annual costs of insulinotherapy, monitoring and tretament of hypoglicae-
mia were estimated in 3-years time horizon. Model was run by having the current
patient cohort progress through the model accompanied by the addition each year
of a new cohort of eligible patients. Extreme scenario sensitivity analyses were
performed. RESULTS: The expected number of diabetic patients eligible for LAIA
would be 12,611 in the 1st year, and each year 661 “new” patients will meet inclu-
sion criteria. Only 25% patients with type 1 and 30% patients with type 2 diabetes
will be successfully treated with LAIA. The introduction of LAIA-TP is expected to
increase public-payers expenditure in years 1st -3th by 12,168,582, 7,972,737 and
8,321,552 PLN, respectively (1 PLN0.25 EURO, 2011). Such an increase in cost would
be associated with acquisition cost of LAIA and would be only partially compen-
sated by lower costs of monitoring and treatment of hypoglicaemia. Depending on
assumptions about population and effectiveness of LAIA the additional expendi-
tures of public payer varies between 11,295,941- 8,962,648 PLN, 7,219,765-9,627,449
PLN and 7,556,552-10,505,485 PLN in 1st, 2nd and 3rd year, respectively.
CONCLUSIONS: Budget impact analysis indicates that reimbursement of LAIA-TP
seems to be affordable to the budget holder.
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OBJECTIVES: Hyperglycaemia is a frequent condition in hospitalizations for acute
conditions, not always correlated with a previous presence of diabetes. Patients
with hyperglycaemia experiment a worse prognosis, with increased mortality,
complications and a longer hospital stay than normal ones. Several evidences in
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